Your email has been successfully added to our mailing list.

×
0 0.13265306122449 0.122448979591837 0.122448979591837 0.801020408163265 1.06122448979592 0.61734693877551 0.443877551020408
Stock impact report

Aslan Pharma to develop ASLAN003 for autoimmune diseases [Seeking Alpha]

ASLAN Pharmaceuticals Ltd ADS (ASLN)  More Company Research Source: Seeking Alpha
US:NASDAQ Investor Relations: ir.aslanpharma.com
PDF ASLAN Pharmaceuticals(NASDAQ:ASLNplansBased on the specificity, potency and favourable safety profile identified in earlier clinical studies, the company believes ASLAN003 is a promising candidate for development in MS and other autoimmune diseases.The company expects to share further details in early 2021.ASLAN003 has been shown to be more than 30 times more potent at inhibiting the DHODH enzyme thanteriflunomide [Read more]
Impact snapshot Event time: ASLN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
ASLN alerts

from News Quantified
Opt-in for
ASLN alerts

from News Quantified